Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04924868
PHASE3

Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis

Sponsor: Hospital General Universitario de Alicante

View on ClinicalTrials.gov

Summary

Acute pancreatitis is a common disease (3rd cause of hospital admission for digestive causes), which is associated with significant patient suffering, a 2-4% probability of death and considerable healthcare costs. Sixty percent of acute pancreatitis are due to the presence of stones in the gallbladder. The risk of suffering another acute biliary pancreatitis (ABP, that is to say, pancreatitis due to gallstones) or of other biliary complications in the following weeks or months is high (20% or greater) if measures are not taken to avoid it, being surgical removal of the gallbladder the most effective. Unfortunately, most Spanish centers have a surgical waiting list that makes gallbladder surgery unfeasible in a period of less than weeks or months, which is why readmission for biliary problems derived from the stones is a common problem. This, of course, causes danger and great stress and anger for patients affected by these complications on the waiting list, damaging their relationship with the health system and it is linked to increased cost. In addition, there is a very vulnerable group, those patients who due to age or serious diseases cannot undergo gallbladder surgery but have a high probability of suffering biliary problems due to the stones they have. Ursodeoxycholic acid (UDCA) is very safe drug which is used to dissolve gallstones, but its role in preventing biliary complications after ABP has not been studied adequately so it is not frequently used. Our objective is to investigate if UDCA is useful in this scenario, which would avoid suffering and adverse consequences for the patient and reduce the consumption of resources.

Official title: Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis, a Double-blind Multicenter Randomized-controlled Trial. OSOPOLAR Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

332

Start Date

2021-11-10

Completion Date

2027-07-01

Last Updated

2025-03-20

Healthy Volunteers

No

Interventions

DRUG

Ursodeoxycholic Acid

Ursodeoxycholic Acid will be administered to patients in the UDCA group as a prophylactic measure of future complications associated to gallstones

DRUG

Placebo

Placebo: composition per 100g: colloidal silica 1.95g and cellulose microcrystalline 98.05g.

Locations (18)

Hospital Clínico Universitario de Santiago

Santiago de Compostela, A coruña, Spain

Hospital General Universitario de Alicante

Alicante, Alicante, Spain

Hospital General Universitario de Elche

Elche, Alicante, Spain

Hospital Univerisitario Vall D´Hebron

Barcelona, Barcelona, Spain

Hospital de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Consorci Corporació Sanitària Parc Taulí de Sabadell

Sabadell, Barcelona, Spain

Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, Spain

Hospital Clínio San Cecilio

Granada, Granada, Spain

Hospital Ramon y Cajal

Madrid, Madrid, Spain

Hospital Costa del Sol,

Marbella, Málaga, Spain

Clinica Unversidad de Navarra

Pamplona, Navarre, Spain

Complejo Hospitalario de Ourense

Ourense, Ourense, Spain

Hospital Universitario Central de Asturias.

Oviedo, Principality of Asturias, Spain

Hospital Clínico Universitario de Valencia

Alicante, Valencia, Spain

Hospital Clínico Universitario de Valladolid

Valladolid, Valladolid, Spain

Hospital Universitario de Cruces

Bilbao, Vizcaya, Spain

Hospital Clínico Lozano Blesa

Zaragoza, Zaragoza, Spain

Hospital Universitario Miguel Servet

Zaragoza, Zaragoza, Spain